FXYD domain containing ion transport regulator 2Genealiases: ATP1G1 · HOMG2
Q-omics provides the consensus-scored FXYD2 profile across patient tissues and cancer cell-line models. FXYD2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FXYD2 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, FXYD2 RNA expression shows 16,359 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KIRP, and GBM as cancer lineages where FXYD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FXYD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FXYD2 survival associations across molecular data types. FXYD2 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FXYD2 RNA expression–survival associations across cancer types. High FXYD2 expression shows unfavorable associations in STAD, but favorable associations in KIRC, BRCA, HNSC, KIRP and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FXYD2 RNA expression.
This table summarizes FXYD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FXYD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FXYD2 shows lower tumor expression in KIRP, KIRC, UCEC, BRCA, HNSC and BLCA. The KIRP box plot shows higher FXYD2 RNA expression in normal versus tumor tissue (log2 FC = −1.705, t-test p < 0.001).
This table shows molecular features associated with FXYD2 in patient tissues and cancer cell lines. In patient samples, FXYD2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FXYD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
